Outcomes of primary radiotherapy with or without chemotherapy for advanced oral cavity squamous cell carcinoma: Systematic review

Abstract

Background Surgery with adjuvant radiotherapy is the accepted standard for treatment of advanced oral cavity squamous cell carcinoma (OCSCC); however, alternative evidence suggests that definitive (chemo)radiotherapy may have similar outcomes. Methods Systematic review was performed to assess the therapeutic value of radiotherapy or chemoradiotherapy as a primary modality for treating OCSCC. Meta‐analysis of outcomes was performed between articles comparing radiotherapy and primary surgical treatment. Results Meta‐analysis showed less favorable results of radiotherapy compared to surgery: overall survival at 3‐years (odds ratio [OR] = 0.51; 95% confidence interval [CI] = 0.34–0.77) and 5‐years (OR = 0.42; 95% CI = 0.29–0.60); disease‐specific survival at 3‐years (OR = 0.55; 95% CI = 0.32–0.96) and 5‐years (OR = 0.55; 95% CI = 0.32–0.96). Odds of feeding tube dependency were higher in primary radiotherapy group (OR = 2.67; 95% CI = 1.27–5.64). Conclusions Results of this study support the current perspective favoring primary surgical treatment for OCSCC in the absence of surgical contraindications.

ThinPrep cytologic test combined with HPV typing to evaluate the degree of cervical diseases and the relationship between HPV typing and the pathological results of patients with atypical squamous cells of undetermined significance: a diagnostic test

“…Surgery or radiotherapy and chemotherapy cause great physical and mental damage to women. Thus, the timely screening of cervical precancerous lesions is key to the prevention and treatment of this disease and in improving the survival rate ( 11 ). Clinical studies have shown that it takes approximately 8–12 years for CIN to develop into invasive cancer.…”

Single-cell transcriptomics uncover the key ferroptosis regulators contribute to cancer progression in head and neck squamous cell carcinoma

“…Head and neck squamous cell carcinoma (HNSCC), which is frequently encountered in the clinical setting, is the seventh leading cause of cancer-related death worldwide: approximately 700,000 new cases and 350,000 deaths were reported worldwide in 2018 ( Membreno et al, 2021 ; Sacco et al, 2021 ). HNSCC mainly includes cancers of the nasal cavity, paranasal sinus, oral cavity, pharynx, and throat, and over 90% of these cancers are squamous cell carcinomas ( Jing et al, 2021 ; Membreno et al, 2021 ).…”

“…Head and neck squamous cell carcinoma (HNSCC), which is frequently encountered in the clinical setting, is the seventh leading cause of cancer-related death worldwide: approximately 700,000 new cases and 350,000 deaths were reported worldwide in 2018 ( Membreno et al, 2021 ; Sacco et al, 2021 ). HNSCC mainly includes cancers of the nasal cavity, paranasal sinus, oral cavity, pharynx, and throat, and over 90% of these cancers are squamous cell carcinomas ( Jing et al, 2021 ; Membreno et al, 2021 ). Although there have been continuous advances in the field of comprehensive surgery, radiotherapy, and chemotherapy in recent years, the 5-year survival rate of HNSCC has not significantly improved, and 30–40% of patients are likely to develop distant metastasis within 5 years ( Membreno et al, 2021 ).…”

“…HNSCC mainly includes cancers of the nasal cavity, paranasal sinus, oral cavity, pharynx, and throat, and over 90% of these cancers are squamous cell carcinomas ( Jing et al, 2021 ; Membreno et al, 2021 ). Although there have been continuous advances in the field of comprehensive surgery, radiotherapy, and chemotherapy in recent years, the 5-year survival rate of HNSCC has not significantly improved, and 30–40% of patients are likely to develop distant metastasis within 5 years ( Membreno et al, 2021 ). Moreover, 58% of patients may have advanced disease (stage III to IV) when they are first diagnosed, and this is a great challenge to treatment ( Hamman et al, 2021 ).…”

“…Moreover, 58% of patients may have advanced disease (stage III to IV) when they are first diagnosed, and this is a great challenge to treatment ( Hamman et al, 2021 ). In order to improve the diagnosis and treatment of this cancer, it is important to understand the cellular mechanisms involved in its progression and metastasis ( Hamman et al, 2021 ; Membreno et al, 2021 ).…”